Deseret Mutual Benefit Administrators Purchases 307 Shares of Johnson & Johnson (NYSE:JNJ)

Deseret Mutual Benefit Administrators increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 12,754 shares of the company’s stock after purchasing an additional 307 shares during the period. Johnson & Johnson accounts for approximately 0.9% of Deseret Mutual Benefit Administrators’ holdings, making the stock its 13th largest position. Deseret Mutual Benefit Administrators’ holdings in Johnson & Johnson were worth $1,864,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Innealta Capital LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at about $27,000. Christopher J. Hasenberg Inc acquired a new position in shares of Johnson & Johnson in the first quarter valued at approximately $31,000. MFA Wealth Advisors LLC bought a new position in shares of Johnson & Johnson during the second quarter worth approximately $43,000. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at $44,000. Finally, Grayhawk Investment Strategies Inc. grew its holdings in Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.4 %

Shares of NYSE JNJ opened at $164.41 on Friday. The company has a market cap of $395.68 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 2.73 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The stock has a 50-day moving average price of $157.57 and a two-hundred day moving average price of $153.83.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same period in the prior year, the company earned $2.80 EPS. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. As a group, analysts forecast that Johnson & Johnson will post 10.02 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on JNJ. TD Cowen dropped their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 30th. TD Securities lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Tuesday. Finally, Morgan Stanley lifted their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.